Bergenbio ASA - Asset Resilience Ratio
Bergenbio ASA (BGBIO) has an Asset Resilience Ratio of 89.96% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check BGBIO strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Bergenbio ASA's Asset Resilience Ratio has changed over time. See Bergenbio ASA net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Bergenbio ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bergenbio ASA stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr140.16 Million | 89.96% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr140.16 Million | 89.96% |
Asset Resilience Insights
- Very High Liquidity: Bergenbio ASA maintains exceptional liquid asset reserves at 89.96% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Bergenbio ASA Industry Peers by Asset Resilience Ratio
Compare Bergenbio ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Bergenbio ASA (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Bergenbio ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 89.96% | Nkr140.16 Million ≈ $14.75 Million |
Nkr155.80 Million ≈ $16.39 Million |
+0.24pp |
| 2023-12-31 | 89.72% | Nkr156.42 Million ≈ $16.46 Million |
Nkr174.34 Million ≈ $18.35 Million |
-0.74pp |
| 2022-12-31 | 90.46% | Nkr150.80 Million ≈ $15.87 Million |
Nkr166.71 Million ≈ $17.54 Million |
-6.52pp |
| 2021-12-31 | 96.98% | Nkr436.65 Million ≈ $45.95 Million |
Nkr450.24 Million ≈ $47.38 Million |
-0.78pp |
| 2020-12-31 | 97.76% | Nkr721.64 Million ≈ $75.94 Million |
Nkr738.20 Million ≈ $77.68 Million |
+3.97pp |
| 2019-12-31 | 93.79% | Nkr253.59 Million ≈ $26.68 Million |
Nkr270.38 Million ≈ $28.45 Million |
-1.35pp |
| 2018-12-31 | 95.14% | Nkr360.41 Million ≈ $37.93 Million |
Nkr378.83 Million ≈ $39.86 Million |
-1.22pp |
| 2017-12-31 | 96.36% | Nkr370.35 Million ≈ $38.97 Million |
Nkr384.34 Million ≈ $40.44 Million |
+3.64pp |
| 2016-12-31 | 92.72% | Nkr161.82 Million ≈ $17.03 Million |
Nkr174.54 Million ≈ $18.37 Million |
-- |
About Bergenbio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.